Lisa A. Carey, MD, and Nadia Harbeck, MD, PhD, on Early HER2-Negative Breast Cancer: Results of the PlanB Trial

2017 ASCO Annual Meeting
Tweet this page

Lisa A. Carey, MD, of the University of North Carolina, and Nadia Harbeck, MD, PhD, of Brustzentrum der Universität München, discuss study findings on adjuvant 4xEC→4x doc vs 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Abstract 504)

Advertisement

Advertisement



Advertisement